Articles From: Pacific Rubiales announces joint venture with ALFA to develop Mexican projects to Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2014 Global London Healthcare Conference


Pacific Rubiales announces joint venture with ALFA to develop Mexican projects Canada NewsWire TORONTO , Dec.
Sign-up for Pacific Rubiales announces joint venture with ALFA to develop Mexican projects investment picks
Pacific Rubiales announces update on its normal courese issuer bid Canada NewsWire TORONTO , Nov.
Sign-up for Pacific Rubiales announces update on its normal courese issuer bid investment picks
TORONTO , Nov.
Sign-up for Pacific Rubiales announces update on its normal courese issuer bid investment picks
TORONTO , Oct.
Sign-up for Pacific Rubiales Applies to Delist its Brazilian Depositary Receipts investment picks
Pacific Rubiales provides 2015 outlook & guidance: $1.5 billion E&D Capex, generating 5 to 8% production growth, fully funded by cash flow at $70/BBL WTI average oil price Canada NewsWire TORONTO , Dec.
Sign-up for Pacific Rubiales provides 2015 outlook & guidance: $1.5 billion E&D Capex, generating 5 to 8% production growth, fully funded by cash flow at $70/BBL WTI average oil price investment picks
Pacific Rubiales provides exploration update: 39 wells drilled, 72% success rate achieved, new production added Canada NewsWire TORONTO , Oct.
Sign-up for Pacific Rubiales provides exploration update: 39 wells drilled, 72% success rate achieved, new production added investment picks
Pacific Rubiales Provides Notice of 2015 Outlook and Guidance Conference Call Canada NewsWire TORONTO , Dec.
Sign-up for Pacific Rubiales Provides Notice of 2015 Outlook and Guidance Conference Call investment picks
Pacific Rubiales provides third quarter 2014 operational update Canada NewsWire TORONTO , Oct.
Sign-up for Pacific Rubiales provides third quarter 2014 operational update investment picks
TORONTO , Oct.
Sign-up for Pacific Rubiales provides third quarter 2014 operational update investment picks
ANAHEIM, Calif., Aug.
Sign-up for Pacific Sunwear Announces Second Quarter Operating Results; Issues Third Quarter Guidance investment picks
ANAHEIM, Calif., Dec.
Sign-up for Pacific Sunwear Announces Third Quarter Operating Results; Issues Fourth Quarter Guidance investment picks
2014/12/3
By Maria Armental Pacific Sunwear of California Inc. swung to a loss in the third quarter, dragged down by a large charge associated with a 2011 loan deal with Golden Gate Capital.
Sign-up for Pacific Sunwear Swings to 3rd-Quarter Loss investment picks
ANAHEIM, Calif., Nov.
Sign-up for Pacific Sunwear to Webcast Conference Call Discussing Third Quarter 2014 Financial Results investment picks
Pacific WebWorks, Inc. (OTCBB: PWEB) today discussed its 2014 third quarter report.
Sign-up for Pacific WebWorks, Inc. Discusses 2014 Third Quarter Report investment picks
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s third quarter ended September 30, 2014, will be released before the market opens on Thursday, October 30, 2014.
Sign-up for Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call investment picks
Pacira Pharmaceuticals, Inc .
Sign-up for Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL® Label investment picks
2014/11/18
Former United States Securities and Exchange Commission attorney Willie Briscoe , founder of The Briscoe Law Firm, PLLC , and the securities litigation firm of Powers Taylor LLP announce that a class action lawsuit has been filed against Pacira Pharmaceuticals, Inc. (“Pacira” or “Company”) (NasdaqGS: PCRX) and several officers and directors for acts taken during the period of April 9, 2012 to September 24, 2014 (the “Class Period”). Based upon the allegations in the class action, the firms are investigating additional legal claims against the officers and Board of Directors of Pacira.
Sign-up for Pacira Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors investment picks
Pacira Pharmaceuticals, Inc .
Sign-up for Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety of EXPAREL® in Peripheral Nerve Block investment picks
Pacira Pharmaceuticals, Inc .
Sign-up for Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter investment picks
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2014.
Sign-up for Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results investment picks
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 26 th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014, at 8:30 a.m. ET in New York.
Sign-up for Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference investment picks
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2014 Global London Healthcare Conference at 10:40 a.m. GMT (5:40 a.m. ET) on Wednesday, Nov.
Sign-up for Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2014 Global London Healthcare Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Pacific Rubiales announces joint venture with ALFA to develop Mexican projects to Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2014 Global London Healthcare Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent